Chloroquine and hydroxycloroquine got the Food and Drug Administration's go-ahead to be put in the nation's strategic storehouses. But the drugs haven't been approved to treat coronavirus patients.

By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.

Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.

It's too soon to know if the antiviral compound tested in 2014 as a potential Ebola treatment will hobble the coronavirus. Lab tests show promise, but studies in people with COVID-19 have only begun.

A vaccine against coronavirus looks to be at least a year away. Doctors are trying existing medicines that might be useful in the meantime. One appears promising.

Fifteen percent of hospital pharmacists who prepare injectable drugs are going without the protective masks they typically rely on, or are using substitutes for the masks.

A new report finds insurers are becoming more selective about which medications they'll cover. Patients and doctors have to work harder to get treatments approved.

New research indicates that insurers are covering far fewer drugs than they did a decade ago. The reduction in options can interrupt care and leave people with hard choices at the pharmacy counter.

In China, drug manufacturers are getting back to work. But supply chain disruptions could still lead to drug shortages down the road.

Two nearly identical drug implants have very different prices. The one for kids has a list price of $37,300. For adults, it's $4,400. A dad fought for his daughter to be able to get the cheaper drug.

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.

Changes in the way the Food and Drug Administration reviews new medicines means that there are more cures and treatments on the market. But there's also less proof the drugs are safe and effective.

The federal government is taking action to pull many flavored products popular with kids off the market. Public health advocates say the move doesn't go far enough.

Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.

The Government Accountability Office found breakdowns in the way the Food and Drug Administration evaluates drugs for rare diseases. The analysis came after an investigation by Kaiser Health News.

More than 70 drugs approved by the FDA from 2001 to 2010 ran into safety concerns that prompted withdrawals from the market, "black box" warnings or other actions.

Amid an uproar over soaring drug prices, three GOP senators are seeking an investigation into whether the Orphan Drug Act is being manipulated to jack up the cost of medications for rare diseases.

Many Duchenne muscular dystrophy patients in the U.S. have imported a medicine called deflazacort for about $1,200 a year. A brand-name version just approved for sale in America costs $89,000.

A half-dozen senators involved in confirmation hearings for Rep. Tom Price to head the Department of Health and Human Services have health care investments made by themselves or family members.

Three decades ago, Congress set up a system to encourage drug companies to develop treatments for rare diseases. The law has worked, but at a high cost.